There’s no sign that the wind­fall of cash drop­ping biotech’s way on Wall Street is abat­ing. Three more bio­phar­mas priced IPOs on Thurs­day and Fri­day morn­ing, rid­ing a his­toric boom with a $364 mil­lion pay­off.

Lon­don-based biotech Free­line Ther­a­peu­tics took home the li­on’s share of the cash with $159 mil­lion af­ter pric­ing 8,823,529 shares at $18 a pop. Check­mate Phar­ma­ceu­ti­cals, of Cam­bridge, MA, raised $75 mil­lion with an of­fer of 5 mil­lion shares at $15 — right at the mid­point of its range. And Arya Sci­ences Ac­qui­si­tion Corp III, the third in a se­ries from Per­cep­tive, priced 13,000,000 shares at $10 per share.

Drug­mak­ers are se­cur­ing big sums amid the pan­dem­ic boom, in­clud­ing AlloVir, which bagged $276 mil­lion from 16.3 mil­lion shares last week. Ini­tial­ly, the com­pa­ny had filed for a $100 mil­lion IPO. By June, all 23 new­ly pub­lic com­pa­nies had priced above their mid­point or up­sized their of­fer­ing.

And there’s more com­ing: Kymera Ther­a­peu­tics an­nounced plans to go pub­lic on Mon­day, when it filed for a $100 mil­lion IPO.

Check­mate ini­tial­ly filed for an IPO on Ju­ly 17, then raised its max­i­mum of­fer­ing price to $92 mil­lion in an amend­ed S-1 fil­ing. The im­muno-on­col­o­gy biotech is in­ves­ti­gat­ing its drug CMP-001 across mul­ti­ple can­cers, in­clud­ing melanoma and head and neck squa­mous cell car­ci­no­ma (HN­SCC), and says it will use the funds to ad­vance clin­i­cal tri­als. Bo­fA Se­cu­ri­ties, Jef­feries Group and BMO Cap­i­tal Mar­kets are man­ag­ing the deal.

CMP-001 us­es the im­mune sys­tem to its ad­van­tage, di­rect­ing ac­ti­vat­ed an­ti-tu­mor T cells to at­tack both the in­ject­ed tu­mor and tu­mors through­out the body. It’s been test­ed on more than 200 melanoma pa­tients to date, and based on clin­i­cal da­ta, the com­pa­ny be­lieves “there is an op­por­tu­ni­ty for CMP-001 to be de­vel­oped as a dif­fer­en­ti­at­ed im­muno-on­col­o­gy ther­a­py,” ac­cord­ing to the S-1 fil­ing.

Free­line ini­tial­ly filed for a $100 mil­lion IPO, with JP Mor­gan Se­cu­ri­ties LLC, Mor­gan Stan­ley & Co. and Ever­core Group as joint bookrun­ners. Its AAV gene-ther­a­py treat­ments tar­get he­mo­phil­ia A and B, Fab­ry dis­ease, and Type 1 Gauch­er dis­ease.

The biotech’s lead can­di­date, FLT180a, is cur­rent­ly in a Phase I/II tri­al for he­mo­phil­ia B. IPO funds will pro­pel the com­pa­ny’s pipeline, in­clud­ing Phase I/II tri­als for FLT180a and FLT190, a po­ten­tial drug to treat Fab­ry dis­ease.

SPACs (spe­cial pur­pose ac­qui­si­tion com­pa­nies) are ben­e­fit­ing from the boom, too. Once rare in the biotech world, they now rep­re­sent near­ly 35% of list­ings, Nas­daq’s Jay Heller told End­points last month.

Per­cep­tive Ad­vi­sors’ blank check com­pa­ny Arya III filed for a $143.7 mil­lion IPO on Ju­ly 21, and in­vestors are bet­ting on a prof­itable merg­er. In March, Arya I merged with biotech Im­mat­ics in a $252 mil­lion deal. Cerev­el Ther­a­peu­tics merged with Arya II in Ju­ly, ex­pect­ing to raise about $445 mil­lion to de­vel­op its pipeline.

Amgen is the latest pharma company to appear on the radar of Senate Finance Committee Chair Ron Wyden (D-OR), who is investigating the way pharma companies are using subsidiaries in low- or zero-tax countries to lower their tax bills.

Like its peers Merck, AbbVie and Bristol Myers Squibb, Wyden notes how Amgen uses its Puerto Rico operations to consistently pay tax rates that are substantially lower than the U.S. corporate tax rate of 21%, with an effective tax rate of 10.7% in 2020 and 12.1% in 2021.

After controversially spinning out its talc liabilities and filing for bankruptcy in an attempt to settle 38,000 lawsuits, Johnson & Johnson is now changing up the formula for its baby powder products.

J&J is beginning the transition to an all cornstarch-based baby powder portfolio, the pharma giant announced on Thursday — just months after a federal judge ruled in favor of its “Texas two-step” bankruptcy to settle allegations that its talc products contained asbestos and caused cancer. An appeals court has since agreed to revisit that case.